Stock RANI RANI THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
6.68 USD +1.83% Intraday chart for Rani Therapeutics Holdings, Inc. -5.52% +101.20%
03-27 Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating MT
03-25 HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating
MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating
MT
Transcript : Rani Therapeutics Holdings, Inc., Q4 2023 Earnings Call, Mar 20, 2024
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
AQ
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Rani Therapeutics : RT-111 Phase 1 Data Presentation
PU
Transcript : Rani Therapeutics Holdings, Inc. - Special Call
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
AQ
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)
CI
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
PR
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope
CI
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
AQ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Rani Therapeutics Stock Climbs After Share Purchase by CEO
MT
Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating
MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RANI Stock
  4. News Rani Therapeutics Holdings, Inc.